A Singaporean pharmaceutical company has developed a new oral drug for Alzheimer’s disease. The results of its phase III clinical trial are positive, which can slow down the decline in cognitive function and brain atrophy in patients. Therapeutic drugs, among which the Taiwanese factory Xufu (4119-TW) is the exclusive raw material drug supplier of this new drug, which will help Xu Fu accelerate its growth and get rid of the decline in recent years.
Xu Fu said that a client developing a new drug for Alzheimer’s disease is expected to apply for a drug license next year, and its factories will also be inspected and certified at the same time. Since the client is very optimistic regarding sales, it is expected to speed up the company’s operations to return to pre-disaster levels.
According to the results of phase III clinical trials of new oral drugs for Alzheimer’s disease announced by TauRx Pharmaceuticals, a Singaporean pharmaceutical company, following early patients received drug treatment, their cognitive ability and brain atrophy continued to improve; compared with patients who had not used drugs in the past, there was Mild to moderate patients treated with drugs had more stable cognitive function and reduced brain atrophy.
With the positive results of clinical trials of new drugs, the company has recently raised US$119 million, and will apply for drug licenses to the competent authorities in the United States, Canada, and the United Kingdom, and will present the research results at the Alzheimer’s Disease Center in San Francisco, USA, which will debut at the end of this month. Clinical Trials in Disease (CTAD) Conference.
Xu Fu expects that the production capacity will gradually recover following getting rid of the haze of the fire. With the continuous shipment of existing product lines, the operation will return to the pre-disaster level in the second half of next year. In the future, it will be produced in the new Guanyin factory, which will drive a significant jump in revenue.
Alzheimer’s disease is a neurodegenerative disease of the brain and a type of dementia. The development of the disease is irreversible and will not cause direct death. Most patients die from other complications. According to statistics, there are regarding 35 million Alzheimer’s patients in the world, of which more than 6 million are in the United States. In 2050, there will be 13 million people, and the business opportunity for drug treatment is as high as 300 billion US dollars.
In fact, the advent of new drugs for Alzheimer’s disease in the United States dates back to 2003. At that time, the annual revenue of the two approved drugs was regarding 1.5 billion US dollars, but the new drug might only alleviate the symptoms caused by Alzheimer’s disease , can not slow down the disease, so many international pharmaceutical companies have invested in the development in recent years, including the joint development of Japan Weicai and Biogen of the United States, Roche Pharmaceuticals, etc.
